中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(10): 2332-2337

Influence of interleukin-6 on the expression and function of programmed death-1 in CD8+ T cells from patients with hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.10.015
  • 1.

    Urinary Surgery, Xi'an People's Hospital, Xi'an 710000, China

  • 2.

    Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

  • 3.

    Department of Infectious Diseases, The Second Affiliated Hospital of Air Force Medical University & Tangdu Hospital of Fourth Military Medical University, Xi'an 710038, China

  • 4.

    Department of Infectious Diseases, Shaanxi Provincial People's Hospital, Xi'an 710068, China

Research funding:

Xi'an Municipal Science and Technology Planning Project (20YXYJ0009〔11〕)

  • Received Date: 2021-02-26
  • Accepted Date: 2021-03-19
  • Published Date: 2021-10-20
    Abstract
  •   Objective  To investigate the influence of interleukin-6(IL-6) on the expression and function of programmed death-1(PD-1) in patients with hepatocellular carcinoma (HCC) by measuring the plasma level of IL-6 and the expression of PD-1 in peripheral blood CD8+ T cells from HCC patients.  Methods  A total of 44 HCC patients who attended Shaanxi Provincial People's Hospital or The Second Affiliated Hospital of Air Force Medical University & Tangdu Hospital of Fourth Military Medical University from January to September 2019 were enrolled as HCC group, and 19 healthy controls, matched for age and sex, were enrolled as HC group. Peripheral blood was collected, and plasma and peripheral blood mononuclear cells were isolated to separate CD8+ T cells. ELISA was used to measure the plasma level of IL-6, and flow cytometry was used to measure the expression level of PD-1 in CD8+ T cells. The separated CD8+ T cells were stimulated with anti-IL-6 neutralizing antibody for 24 hours; CCK-8 assay was used to measure cell proliferation, ELISA was used to measure the levels of interferon-γ (IFNγ) and tumor necrosis factor-α (TNFα) in supernatant, real-time PCR was used to measure the relative mRNA expression levels of perforin, granzyme B, and granulysin, and Western blot was used to measure the phosphorylation levels of STAT3 and Src. The t-test or the paired t-test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between groups.  Results  Compared with the HC group, the HCC group had a significant increase in the plasma level of IL-6 (99.67±20.92 pg/mL vs 81.05±16.76 pg/mL, t=3.427, P=0.001 1). There was no significant difference in the percentage of CD3+CD8+ T cells between the HCC group and the HC group, while there was a significant increase in the percentage of PD-1+CD8+ cells in HCC patients (3.79%±1.36% vs 2.20%±0.47%, t=5.335, P < 0.000 1). In the patients with HCC, although anti-IL-6 neutralizing antibody for inhibiting IL-6 in CD8+ T cells did not affect cell proliferation, it downregulated the expression of PD-1 (2.67%±0.91% vs 3.33%±1.12%, t=2.177, P=0.035) and increased the secretion of IFNγ (13.50±3.82 pg/mL vs 10.82±1.37 pg/mL, t=3.170, P=0.002 8), and there were also significant increases in the relative mRNA expression levels of perforin and granzyme B (t=6.161 and 14.140, both P < 0.000 1) and a significant reduction in the level of phosphorylated STAT3 (P < 0.000 1).  Conclusion  Anti-IL-6 neutralizing antibody can enhance the function of CD8+ T cells in HCC patients possibly by increasing the levels of perforin and granzyme B, improving the secretion of cytokines, and inhibiting the expression of PD-1.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    MCLANE LM, ABDEL-HAKEEM MS, WHERRY EJ. CD8 T cell exhaustion during chronic viral infection and cancer[J]. Annu Rev Immunol, 2019, 37: 457-495. DOI: 10.1146/annurev-immunol-041015-055318.
    [2]
    MILLER BC, SEN DR, AL ABOSY R, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade[J]. Nat Immunol, 2019, 20(3): 326-336. DOI: 10.1038/s41590-019-0312-6.
    [3]
    GALLUZZI L, HUMEAU J, BUQUÉ A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2020, 17(12): 725-741. DOI: 10.1038/s41571-020-0413-z.
    [4]
    DOLLADILLE C, EDERHY S, SASSIER M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer[J]. JAMA Oncol, 2020, 6(6): 865-871. DOI: 10.1001/jamaoncol.2020.0726.
    [5]
    ERIKSSON E, MILENOVA I, WENTHE J, et al. IL-6 signaling blockade during CD40-mediated immune activation favors antitumor factors by reducing TGF-β, collagen type I, and PD-L1/PD-1[J]. J Immunol, 2019, 202(3): 787-798. DOI: 10.4049/jimmunol.1800717.
    [6]
    LOKAU J, SCHOEDER V, HAYBAECK J, et al. Jak-stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma[J]. Cancers (Basel), 2019, 11(11): 1704. DOI: 10.3390/cancers11111704.
    [7]
    Bureau of Medical Administrationnational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [8]
    HOU H, KANG Y, ZENG Y, et al. Interleukin-7 augments CD8(+) T cells function and promotes viral clearance in chronic hepatitis C virus infection[J]. Cytokine, 2018, 102: 26-33. DOI: 10.1016/j.cyto.2017.12.014.
    [9]
    YANG YM, KIM SY, SEKI E. Inflammation and liver cancer: Molecular mechanisms and therapeutic targets[J]. Semin Liver Dis, 2019, 39(1): 26-42. DOI: 10.1055/s-0038-1676806.
    [10]
    BOMMARITO D, HALL C, TAAMS LS, et al. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1[J]. Clin Exp Immunol, 2017, 188(3): 455-466. DOI: 10.1111/cei.12949.
    [11]
    YIN Z, MA T, LIN Y, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma[J]. J Cell Biochem, 2018, 119(11): 9419-9432. DOI: 10.1002/jcb.27259.
    [12]
    BERGMANN J, MVLLER M, BAUMANN N, et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice[J]. Hepatology, 2017, 65(1): 89-103. DOI: 10.1002/hep.28874.
    [13]
    LI Y, CHEN G, HAN Z, et al. IL-6/STAT3 signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells[J]. Onco Targets Ther, 2020, 13: 9721-9730. DOI: 10.2147/OTT.S262089.
    [14]
    YANG J, WANG J, LUO J. Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib[J]. Pathol Res Pract, 2019, 215(10): 152565. DOI: 10.1016/j.prp.2019.152565.
    [15]
    ALSAAB HO, SAU S, ALZHRANI R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017, 8: 561. DOI: 10.3389/fphar.2017.00561.
    [16]
    TSUKAMOTO H, FUJIEDA K, MIYASHITA A, et al. Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment[J]. Cancer Res, 2018, 78(17): 5011-5022. DOI: 10.1158/0008-5472.CAN-18-0118.
    [17]
    LIU H, SHEN J, LU K. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model[J]. Biochem Biophys Res Commun, 2017, 486(2): 239-244. DOI: 10.1016/j.bbrc.2017.02.128.
    [18]
    ZHANG W, LIU Y, YAN Z, et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(1): e000285. DOI: 10.1136/jitc-2019-000285.
    [19]
    WU W, DIETZE KK, GIBBERT K, et al. TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection[J]. Sci Rep, 2015, 5: 10501. DOI: 10.1038/srep10501.
    [20]
    ZHOU X, HOPKINS JW, WANG C, et al. IL-2 and IL-6 cooperate to enhance the generation of influenza-specific CD8 T cells responding to live influenza virus in aged mice and humans[J]. Oncotarget, 2016, 7(26): 39171-39183. DOI: 10.18632/oncotarget.10047.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (831) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return